Skip to main content
Home

Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE),  American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA). 

RSS icon

  • older patient with a doctor at their house

    Persistent mitral regurgitation after TAVR more common among women than men

    The study's authors emphasized that these data should be kept in mind when making treatment decisions for female patients with severe AS. 

  • Heart attack patients treated at for-profit hospitals more likely to be readmitted

    Readmission rates are getting lower over time among patients treated at nonprofit hospitals. At for-profit facilities, meanwhile, readmission rates have stayed relatively unchanged.

  • A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

    High-quality heart failure care is easy to find for many Americans—but care gaps remain

    The Heart Failure Society of America has released a new comprehensive look at HF clinics in the United States. The report includes more than 300 programs that serve approximately 626,000 patients.

  • obesity semaglutide tirzepatide GLP-1 drugs weight loss

    Semaglutide is improving the heart health of millions—but how? Experts are stumped

    “Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty,” one researcher said after exploring years of data. "These results suggest that semaglutide should be considered as a cardiovascular disease reduction drug and not just as a weight loss drug." 

  • artificial intelligence AI heart cardiology

    AI uses routine CT images to evaluate cardiovascular risk

    Researchers have trained a new AI model to read routine medical images and deliver accurate cardiovascular age assessments.

Angiography demonstrates a high-grade, modestly angulated stenosis (arrow) in the proximal segment of a large diagonal branch (A). Predilation performed with difficulty, and the GEC could not be advanced beyond stenosis even with “inch worming” techniques. (B). Advancement of the CrossFAST (C) beyond the proximal stent edge stenosis (a.), the position of the distal end of the outer catheter (b.), and the microcatheter tip (c.) are indicated.

Next-generation guide extension catheter delivers value during complex PCI

The CrossFAST system was successfully used to deploy multiple stents after other devices fell short. 

Semaglutide, the GLP-1 receptor agonist sold by Novo Nordisk under the brand names Wegovy and Ozempic, is associated with significant health benefits for patients with type 2 diabetes and peripheral artery disease (PAD), according to a late-breaking clinical trial presented at ACC.25, the annual meeting of the American College of Cardiology (ACC).

American College of Cardiology announces late-breaking clinical trials for ACC.26

The American College of Cardiology's 2026 annual meeting will include an all-time record of 60 late-breaking clinical studies.

robot reviewing heart data

Cardiologists develop new AI screening tool for structural heart disease

Researchers have developed an advanced AI model capable of detecting signs of severe AS, mitral regurgitation and other complications in ECG results. For example, one 84-year-old patient who was hospitalized for a fractured femur ended up being scanned and treated with TAVR just days later.

Thumbnail

World’s first polymeric TAVR valve impresses cardiologists—could improve durability, reduce costs

The new-look TAVR system was linked to multiple benefits after one year. The cardiologists evaluating this device belief it could significantly reduce the risk of long-term valve degeneration.

The Relief System from Relief Cardiovascular Inc. is a first of its kind device. It incorporates a valve and sensor implant that uses AI to intelligently modulate venous pressure using hemodynamic data. The system actively adjusts flow in the inferior vena cava (IVC), which lowers venous pressure to drive durable decongestion in heart failure.

New AI-enabled heart failure implant shows early potential

The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home. 

Thumbnail

Heart failure biomarker identifies long-term risk in T-TEER patients

NT-proBNP measurements are often used to diagnose and manage heart failure. According to a new study of more than 2,000 patients, they can also provide value to cardiologists performing T-TEER.

artificial intelligence AI policy washington capitol

Cardiology groups to Trump administration: AI still has a long way to go

Multiple cardiology societies responded to an HHS request for public feedback by outlining some of the current barriers to wider AI adoption. "It is essential that any policy frameworks must reaffirm that clinicians—not algorithms—remain at the center of patient care," ACC President Christopher Kramer, MD, said. 

After traversing the aortic cusp with an electrified wire and balloon inflation, a stent is positioned inside the noncoronary cusp and deployed. Immediately after, a transcatheter aortic valve is expanded, and the stent is crushed on the left ventricular outflow tract wall and annulus, while anchored to the aortic valve leaflet.

Cardiologists perform first TAVR of its kind by anchoring valve to crushed stent

The patient, 78, presented with severe AR and no signs of calcification. She was considered a poor choice for surgery or traditional TAVR due to multiple risks. That is where the new-look ATLAS technique came in.

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …25
    • Page 26
    • Page 27
    • Page 28
    • Current page 29
    • Page 30
    • Page 31
    • Page 32
    • Page 33 …
    • Next page Next ›
    • Last page Last »
Displaying 225 - 232 of 1678
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme